August's manufacturing rebound is too modest and too concentrated to signal a recovery. Household consumption of goods fell by 0.5% in August. Read more here.
Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. Learn more about ZVRA stock here.
Manufacturing output rose globally in September at its fastest rate since July 2021, reflecting production growth in 22 of the 33 countries covered by the S&P Global PMI surveys.
International Seaways' H1 FY2026 TCE revenue and net income surged 104.7% and 422.5% YoY, driven by elevated spot charter rates. Read why INSW stock is a buy.
Marcus' theatres outperformed the domestic box office, with revenue up 14.4% and adjusted EBITDA margin reaching 18.7% LTM. Read why MCS stock is a Buy.